Amedisys Inc

Amedisys — Q1 2021 Earnings Presentation

18 slides from Amedisys's earnings presentation, Apr 28, 2021

  1. Slide 1: Amedisys First Quarter 2021 Earnings Call Supplemental Slides

    Amedisys First Quarter 2021 Earnings Call Supplemental Slides April 29th, 2021 Exhibit 99.2

  2. Slide 2: Forward-looking statements

    This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and uncertainties that could cau

  3. Slide 3: Our Key Areas of Focus

    Our Key Areas of Focus Strategic areas of focus and progress made during Q1’21 Home Health*: Total same store admissions +5%, Total same store volume +6% Hospice: Admissions +5% Personal Care: Billable hours / quarter -19% driven by impact of COVID-19. Personal Care Network drove ~$1.2 revenue to Ho

  4. Slide 4: Highlights and Summary Financial Results (Adjusted): 1Q 2021

    Highlights and Summary Financial Results (Adjusted): 1Q 2021(1) Home Health total same store volume +6%, total same store admissions +5%; Hospice same store admissions +5% Amedisys Consolidated Revenue Growth: +9% EBITDA: $79M (+47%) EBITDA Margin: 14.6% (+380 bps) EPS: $1.54 (+47%) 1Q’21 Net debt:

  5. Slide 5: Our Revenue Sources: 1Q'21

    Medicare FFS: Reimbursed over a 30-day period of care Private Episodic: MA and Commercial plans who reimburse us over a 30-day period of care, generally at rates ~90% – 100% of Medicare Per Visit: Managed care, Medicaid and private payors reimbursing us per visit performed Hospice Per Day Reimbursem

  6. Slide 6: Home Health and Hospice Segment (Adjusted) – 1Q 2021

    Home Health and Hospice Segment (Adjusted) – 1Q 2021(1) Revenue per Episode up 7.2% (sequestration suspension and 2021 rate increase +1.9%) Y/Y CPV up $4.64 (+5.0%, primarily due to an increase in contractor utilization) Visits per Episode decreased 1.9 (~$10M) Home Health Highlights Same store admi

  7. Slide 7: General & Administrative Expenses – Adjusted

    General & Administrative Expenses – Adjusted (1,2) Notes: Year over year total G&A as a percentage of revenue increased 40 basis points ($16 million) Year over year G&A increase due to the AseraCare acquisition (~$8M = Hospice segment ~$7M; Corporate segment ~$1M), raises, higher health insurance co

  8. Slide 8: Cost per Visit Components

    Components 1Q’20 4Q’20 1Q’21 YoY Variance Detail Initiatives Salaries $64.42 $66.09 $64.54 $0.12 YoY increase due to planned wage increases and inclement weather pay, partially offset by optimization of discipline mix. Sequential decrease due to one less holiday and lower fixed new hire pay due to t

  9. Slide 9: Driving Top Line Growth

    Driving Top Line Growth Home Health total volume growth remains strong. Hospice admissions down from Q4-2020 levels; ADC lagging due to lower admissions, an increase in our discharge rate and delays in timing of patients coming onto service. Personal Care billable hours impacted by COVID-19 Home Hea

  10. Slide 10: Industry Leading Quality Scores

    Industry Leading Quality Scores Note: Top Competitor Avg weighted by CCN count and includes LHC, Kindred, AFAM, EHC and BKD Metric OCT 19 Release JAN 20 Release APR 20 Release Oct 20 Release Quality of Patient Care 4.28 4.27 4.26 4.33 Entities at 4+ Stars 88% 86% 86% 92% Metric OCT 19 Release JAN 20

  11. Slide 11: Hospice Quality: Moving Towards Best-in-Class Hospice Quality

    Hospice Quality: Amedisys Hospice Continues to Move Towards Best-in-Class Hospice Quality Hospice Compare HIS and CAHPS reporting currently “frozen” and will resume reporting in Feb 2022

  12. Slide 12: Debt and Liquidity Metrics

    Debt and Liquidity Metrics ~Net leverage ~0.7x Net debt defined as total debt outstanding ($244.2M) less cash ($22.3M). Leverage ratio (net) is defined as net debt divided by last twelve months adjusted EBITDA ($298.8M). Liquidity defined as the sum of cash balance and available revolving line of cr

  13. Slide 13: Cash Flow Statement Highlights

    Cash Flow Statement Highlights (1) Q2’20, Q3’20 and Q4’20 include benefit of payroll tax deferral (COVID-19 relief) of approximately $20M, $18M and $17M respectively. Q4’20 also includes ~$15M in additional tax payments related to treatment of CARES Act funds. Total payroll tax deferral of ~$55.4M d

  14. Slide 14: Income Statement Adjustments

    Income Statement Adjustments (1) The financial results for the three-month periods ended March 31, 2020, June 30, 2020, September 30, 2020, December 31, 2020 and March 31, 2021 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP fi

  15. Slide 15: 2021 Guidance

    2021 Guidance 6 amedisys

  16. Slide 16: Amedisys 2021 Updated Guidance

    Amedisys 2021 Updated Guidance Note: Adjusted numbers are ex-CARES Act funds Updated Revenue, EBITDA and EPS guidance ranges for FY 2021 to reflect the extension of the suspension of sequestration through December 31, 2021 2021 Original Guidance 2021 Updated Guidance Revenue Adjusted EBITDA Adjusted

  17. Slide 17: 2021 Guidance Considerations

    2021 Guidance Considerations Amedisys Consolidated Tax rate ~26% Cash tax rate ~15% Diluted share count ~33.4 million shares Capital Expenditures ~$6-$8 million Salary increase ~2% - 3% Benefits increase ~14% (9% growth / headcount, 5% pricing / claims costs) Overall ~$10 million investment in busin

  18. Slide 18: 2021 Hospice ADC Projection

    2021 Hospice ADC Projection On track at the end of Q1’21 due to improvement in length of stay ADC impact developed in late Q4 AseraCare Acquisition

Amedisys — Q1 2021 Earnings Presentation on 6ix